.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Serving leading biopharmaceutical companies globally:

Argus Health
Federal Trade Commission
Teva
Dow
Johnson and Johnson
Harvard Business School
Colorcon
McKesson
Chubb
Accenture

Which pharmaceutical companies have the most SPCs in Finland?

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland.

SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long time needed to obtain regulatory approval for drugs. SPCs come into force only after the corresponding general patent expires, and normally have a maximum lifetime of 5 years.

The total combined duration of market exclusivity of a general patent and SPC cannot normally exceed 15 years, but a six-month extention may be obtained by responding to a request for pediatric trials.

For a different perspective, see the drug companies with SPCs in the most countries

The pharma companies with the most SPCs in Finland are:

Back to Pharmaceutical Industry Infographics

For more information try a trial or see the plans and pricing

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot